| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/06/2011 | EP2303259A1 Dronedarone for the prevention of cardioversion |
| 04/06/2011 | EP2303258A1 Inhibitors of akt activity |
| 04/06/2011 | EP2303257A1 Rosmarinic acid from origanum vulgare for treatment of diabetes |
| 04/06/2011 | EP2303256A1 Compounds useful for the prevention or treatment of accomodative asthenopia |
| 04/06/2011 | EP2303255A1 Pharmaceutical compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia |
| 04/06/2011 | EP2303254A2 Method for treating chronic wounds with an extracellular polymeric substance solvating system |
| 04/06/2011 | EP2303253A2 Methods and compositions for improving cognitive function |
| 04/06/2011 | EP2303252A1 Compounds for the treatment of metabolic syndrome and insulin resistance |
| 04/06/2011 | EP2303251A1 New combination for use in the treatment of inflammatory disorders |
| 04/06/2011 | EP2303250A1 Paediatric compositions for treating1 multiple sclerosis |
| 04/06/2011 | EP2303249A2 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions |
| 04/06/2011 | EP2303243A1 Oral composition containing an anti-plaque agent of the thienopyridine family in the form of a base |
| 04/06/2011 | EP2303240A1 Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| 04/06/2011 | EP2303239A1 Directly pressed aliskiren tablets |
| 04/06/2011 | EP2303238A1 Solid dosage formulations of telcagepant potassium |
| 04/06/2011 | EP2303235A2 Stabilization of amorphous drugs using sponge-like carrier matrices |
| 04/06/2011 | EP2303233A1 Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
| 04/06/2011 | EP2303232A1 Micronisable form of salmeterol xinafoate |
| 04/06/2011 | EP2303231A1 Preparation containing glucosamine and/or chondroitin for prophylaxis and treatment of arthrosis and for supporting the immune system |
| 04/06/2011 | EP2303229A1 Concentrated oxaliplatin solution and its method of preparation |
| 04/06/2011 | EP2303228A1 Fosphenytoin composition |
| 04/06/2011 | EP2303227A2 Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 04/06/2011 | EP2303225A2 Process for preparing a carbapenem antibiotic composition |
| 04/06/2011 | EP2303184A1 Combination treatment of glaucoma |
| 04/06/2011 | EP2303040A1 Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon |
| 04/06/2011 | EP2303036A1 Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| 04/06/2011 | EP2303026A1 Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
| 04/06/2011 | EP2303025A1 Methods for treating visceral fat conditions |
| 04/06/2011 | EP2303021A2 Compounds for the treatment of cancer |
| 04/06/2011 | EP2303020A1 Preparation of controlled release skeletal muscle relaxant dosage forms |
| 04/06/2011 | EP2303019A1 (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury |
| 04/06/2011 | EP2303018A1 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
| 04/06/2011 | EP2303017A1 Inhibitors of akt activity |
| 04/06/2011 | EP2303013A1 Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
| 04/06/2011 | EP2275089A9 Preparation of biodegradable microparticles containing a biologically active agent |
| 04/06/2011 | EP2185510B1 New salts of bazedoxifene |
| 04/06/2011 | EP2125788B1 Heterocyclic compounds, compositions comprising them and methods of their use |
| 04/06/2011 | EP2114407B1 Use of sodium blockers for an early therapy of obstructive lung diseases |
| 04/06/2011 | EP2094675B1 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one |
| 04/06/2011 | EP2091925B1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same |
| 04/06/2011 | EP2059518B1 Salts of benzimidazolyl pyridyl ethers and formulations thereof |
| 04/06/2011 | EP2059304B1 Treating mycobacterial infections with cyclipostins |
| 04/06/2011 | EP2046787B1 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| 04/06/2011 | EP2000473B1 Trehalose compound and pharmaceutical comprising the compound |
| 04/06/2011 | EP1965773B1 Oral formulation of anhydrous olanzapine form i |
| 04/06/2011 | EP1945228B1 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| 04/06/2011 | EP1919865B1 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors |
| 04/06/2011 | EP1915198B1 Visnadin for treating scalp skin itching |
| 04/06/2011 | EP1888592B1 Spiroheterocyclic compounds and their uses as therapeutic agents |
| 04/06/2011 | EP1878431B1 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues |
| 04/06/2011 | EP1857107B1 Preventive or therapeutic agent for cardiac dysfunction or myocardial damage caused by ischemia or ischemia-reperfusion |
| 04/06/2011 | EP1848414B1 Method for treating gefitinib resistant cancer |
| 04/06/2011 | EP1846378B1 Cationic lipids for the transfection of nucleic acids |
| 04/06/2011 | EP1828151B1 Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer's disease |
| 04/06/2011 | EP1814849B1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/06/2011 | EP1805160B1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 04/06/2011 | EP1780197B9 5-substituted-2-phenylamino benzamides as mek inhibitors |
| 04/06/2011 | EP1721157B1 Use of antibodies to tweak for the treatment of stroke |
| 04/06/2011 | EP1711185B1 Combination of roscovitine cs-682 or its metabolite cndac |
| 04/06/2011 | EP1709053B1 Stable salts of olanzapine |
| 04/06/2011 | EP1685832B1 Nerve regeneration promoters |
| 04/06/2011 | EP1684715B1 Compositions comprising neramexane |
| 04/06/2011 | EP1663145B1 Oros-push-stick for controlled delivery of active agents |
| 04/06/2011 | EP1628968B1 4-imidazolin-2-one compounds |
| 04/06/2011 | EP1602660B1 Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators |
| 04/06/2011 | EP1596870B2 High dose ibandronate formulation |
| 04/06/2011 | EP1594889B1 Nell peptide expression systems and bone formation activity of nell peptide |
| 04/06/2011 | EP1558259B1 Urea derivatives as IL-8 receptor antagonists |
| 04/06/2011 | EP1545483B1 Non-nucleoside reverse transcriptase inhibitors |
| 04/06/2011 | EP1519939B9 N-aryl diazaspirocyclic compounds and methods of preparation and use thereof |
| 04/06/2011 | EP1469876B1 Antimicrobial cationic peptides and formulations thereof |
| 04/06/2011 | EP1411979B1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 04/06/2011 | EP1404356B1 Method for designing cd10-activated prodrug compounds |
| 04/06/2011 | EP1404324B2 Prodrugs of gaba analogs, compositions and uses thereof |
| 04/06/2011 | EP1370277B1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis |
| 04/06/2011 | EP1353911B1 Antiviral agents |
| 04/06/2011 | EP1328236B1 Methods of decreasing or preventing pain using spicamycin derivatives |
| 04/06/2011 | EP1303522B1 Biologically active macrolides, compositions, and uses thereof |
| 04/06/2011 | EP1303479B1 7-, 8- and 9-substituted tetracycline compounds |
| 04/06/2011 | CN1993332B Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors |
| 04/06/2011 | CN1993119B Composition containing statins and omega-3 fatty acids |
| 04/06/2011 | CN1981869B Compound non-carrier antibacterial eye drops containing practofren and its production |
| 04/06/2011 | CN1970547B Novel febuxostat crystal form and its preparation method |
| 04/06/2011 | CN1946680B 非核苷逆转录酶抑制剂 Non-nucleoside reverse transcriptase inhibitors |
| 04/06/2011 | CN1910284B Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same |
| 04/06/2011 | CN1905864B DNA damage repair inhibitors for treatment of cancer |
| 04/06/2011 | CN1902158B N,N-dihalogenated amino acids and derivatives |
| 04/06/2011 | CN1887875B Pyridazinyl amine derivative and its use in preparing small RNA virus inhibitor |
| 04/06/2011 | CN1886143B Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s) |
| 04/06/2011 | CN1859909B Solid dispersions comprising tacrolimus |
| 04/06/2011 | CN1858040B 5,8-disubstituted quinazoline and its preparing method and use |
| 04/06/2011 | CN1812980B Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics |
| 04/06/2011 | CN1785991B Anti inflammatory detoxication luteolin kind derivative and its preparation method |
| 04/06/2011 | CN1762495B Long acting sustained-release formulation containing dopamine-receptor stimulant medicine and its preparation process |
| 04/06/2011 | CN1730476B Aromatic amine ketone compounds, its synthesis method, pharmaceutical composition containing same and uses |
| 04/06/2011 | CN1660335B Dripping heart pill preparation for alleviating pains of heart and stomach |
| 04/06/2011 | CN1649612B Induction method for cell differentiation |
| 04/06/2011 | CN1376146B Solid-state form of celecoxil having enhanced bioavailability |
| 04/06/2011 | CN102007138A Hemifumarate of a pyrazole derivative |
| 04/06/2011 | CN102007134A Copper organocomplexes, use thereof as antitumor means and for protecting healthy tissue from ionizing radiation |